PTC Therapeutics, Inc. Total Liabilities
PTC Therapeutics, Inc. (PTCT) had Total Liabilities of $3.42 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-30
- 2026-06-30: Liabilities $3.42B.
- 2026-03-31: Liabilities $3.05B.
- 2025-12-31: Liabilities $3.10B.
- 2025-09-30: Liabilities $2.80B.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $3.42B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $3.05B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $3.10B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $2.80B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $2.84B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $2.84B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $2.80B 10-K · filed 2026-02-19 | |
| 2024-09-30 | $2.90B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.90B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.68B 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $2.71B 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.93B 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $1.92B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $2.07B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $2.05B 10-K · filed 2024-02-29 | |
| 2022-09-30 | $1.80B 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $1.99B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.89B 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $1.94B 10-K · filed 2023-02-21 | |
| 2021-09-30 | $1.90B 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $1.86B 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $1.82B 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $1.73B 10-K · filed 2022-02-22 | |
| 2020-09-30 | $1.67B 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $904.14M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $1.02B 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $1.03B 10-K · filed 2021-02-25 | |
| 2019-09-30 | $977.83M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $802.89M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $770.97M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $768.50M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $642.54M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $244.37M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $229.10M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $235.22M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $221.84M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $213.35M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $147.82M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $149.76M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $148.00M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $139.94M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $139.23M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $139.28M 10-K · filed 2017-03-16 | $142.04M 10-K · filed 2016-02-29 |
| 2015-09-30 | $126.95M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $25.24M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $26.20M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $34.75M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $19.50M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $13.80M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $11.50M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $15.36M 10-K · filed 2015-03-02 | $15.36M 10-K · filed 2014-03-06 |
| 2013-09-30 | $16.21M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $22.55M 10-Q · filed 2013-08-13 | |
| 2012-12-31 | $31.89M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |